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Viral vectors available for gene therapy are either inefficient or suffer from safety concerns for human applications. Foamy viruses are non-
pathogenic retroviruses that offer several unique opportunities for gene transfer in various cell types from different species. In this report, we
describe the use of simian foamy virus type 1 (SFV-1) vector to examine the efficacy of therapeutic genes. Hairpin short-interfering RNA (siRNA)
that targets the simian immunodeficiency virus (SIV) rev/env was placed under the control of the PolIII U6 snRNA promoter for expression and
screened for silencing target genes using cognate target– reporter fusions. We have identified an effective siRNA (designated R2) which reduces
the rev and env gene expression by 89% and 95%, respectively. Using the simian foamy virus type 1 (SFV-1) based vector, we delivered the PolIII
expressed R2 siRNA into cultured cells and challenged with SIV. The results show that the R2 siRNA is a potent inhibitor of SIV replication as
determined by p27 expression and reverse transcriptase assays. Vectors based on a non-pathogenic SFV-1 vector may provide a safe and efficient
alternative to currently available vectors, and the SIV model will help devise protocols for effective anti-HIV gene therapy.
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One of the major problems in gene therapy is the low
transduction efficiency in target tissues. Although various
vector systems are available, there is still a growing demand for
a suitable gene transfer vehicle. Currently available vehicles for
gene transfer are either inefficient or potentially unsafe for
human gene therapy applications. Foamy viruses offer a fresh
alternative vector system for gene transfer. These viruses are
members of the spumavirus subfamily of retroviruses and have
several inherent features that make them ideal for constructing
retroviral vectors to deliver heterologous genes in many species
and cell types. First, foamy viruses can be propagated
efficiently in various cell types of several species such as
cultured epithelial and fibroblast cells as well as lymphoid and
neural originated cells which support the growth of foamy0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: mergiaa@mail.vetmed.ufl.edu (A. Mergia).viruses (Hill et al., 1999; Mergia and Heinkelein, 2003; Mergia
et al., 1996). Each foamy virus isolate is known to infect
several mammalian species from which virus can be recovered
from many organs (Hooks and Detrick-Hooks, 1981). Second-
ly, to date, no disease has been connected to foamy virus in
naturally as well as experimentally infected animals (Flugel,
1991; Linial, 2000; Mergia and Luciw, 1991; Weiss, 1988).
Humans are not natural hosts of foamy viruses; however,
hunters in Central Africa and occupational infections with
primate foamy virus isolates have been reported (Callahan et
al., 1999; Heneine et al., 1998; Schweizer et al., 1997;
Schweizer et al., 1995; Wolfe et al., 2004). Animal caretakers
accidentally infected with SFV remain healthy with no
secondary human to human transmission being detected
(Heneine et al., 1998). Thirdly, reverse transcription occurs
late in the replication cycle of foamy viruses before the virion
is released from the infected cell and that at least 20% of the
released virions contain fully reverse transcribed infectious
DNA (Enssle et al., 1997; Yu et al., 1996, 1999). This may
provide an edge for foamy virus vectors over the other5) 275 – 282
www.e
Fig. 1. Inhibition of the expression of Rev-GFP fusion protein by the R2
siRNA. (A) Northern blot analysis of PolIII U6 promoter driven R2 siRNA
expression. RNAwas isolated from 293T cells 2 days post-transfection. The top
panel is blot hybridized with a [g-32P]ATP-labeled antisense strand of the R2
siRNA. The bottom panel is blot probed with U6 RNA-specific oligonucleotide
probe. Lane 1 is RNA isolated from mock-transfected cells. Lane 2 represents
RNA samples transfected with plasmid containing the U6 promoter only. The
RNA sample from cells receiving the R2 siRNA expression cassette is in Lane
3. Synthetic hairpin R2 and sense strand R2 DNAs are in Lanes 4 and 5
respectively. (B) Inhibition of GFP expression by siRNA that targets the SIV
rev gene. Each of the siRNA expression cassette that targets rev (R1, R2 or R3
was co-transfected with Rev-GFP expression plasmid. Two days post-
transfection, the cells were harvested and analyzed for GFP expression by
FACS. The results shown are from triplicate experiments. (C) The efficacy o
varying concentrations of the R2 siRNA on Rev-GFP fusion protein
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at the point of reverse transcription. Finally, foamy virus
vectors can transduce stationary/quiescent cells efficiently
(equivalent to the HIV vectors) but require mitosis for
transgene expression (Patton et al., 2004; Trobridge and
Russell, 2004). The foamy virus genome persists in non-
dividing cells for at least 10 days. Whether the genome stays
episomally in none dividing cells remains to be determined.
Nevertheless, the high transduction in non-dividing cells will
make foamy virus an effective vector compared to retroviral
vectors that require cell division for efficient transduction.
Principle information for the design of foamy virus vectors
is worked out and several foamy virus vectors that efficiently
transduce a variety of cell types from different species are
available (Reviewed in Mergia and Heinkelein, 2003). Foamy
virus vectors can efficiently transduce human hematopoietic
cells obtained from umbilical cord blood at low multiplicity of
infections (Josephson et al., 2002). The severe combined
immunodeficiency (SCID) recipients of transduced CD34+
human hematopoietic cells express the vector-encoded trans-
gene in all hematopoietic cell lineages analyzed. Transduction
efficiencies in the range of 64–92% in SCID repopulating cells
using the prototype foamy virus 1 (PFV, originally human
foamy virus) vector, containing a transgene under the control of
murine stem cell virus promoter were reported, indicating that
foamy virus vectors are ideal vehicles for human gene therapy
(Josephson et al., 2002). Furthermore, a comparative study of
transduction efficiencies in CD34+ cells revealed that foamy
virus vectors are superior to that of HIV vectors (Leurs et al.,
2003). Efficient transduction of foamy virus vector into blood
cells has implications for the use of foamy virus based vectors
in immunodeficiency virus gene therapy. In this report, we
provide the use of a simian foamy virus type 1 (SFV-1) vector
to examine the efficacy of therapeutic genes and thus
demonstrate inhibition of simian immunodeficiency virus
replication in cells transduced with SFV-1 vectors containing
siRNA molecules.
Results
Inhibition of SIV Rev expression by siRNAs
Short hairpin siRNAs that target the rev gene selected from
three different regions (R1, R2 and R3, Table 1) were designed
as previously described (Paul et al., 2002). Each siRNA was
placed under the control of the PolIII U6 snRNA promoter for
expression. The expression of siRNAs was monitored by
Northern blot analysis; a representative Northern blot for
siRNA expression from 293T cells transfected with 2 Ag of
plasmid containing the R2 siRNA expression cassette is shownTable 1
siRNA target sequences
siRNA Target sequence Target gene Location
R1 ggcggtggcaacagctcct 9125–9143
R2 ctgatacgcctcttgactt SIV rev 9185–9203
R3 ctccagaggctctctgcga 9261–9279
expression. Cells were transfected with the indicated pU6R2/pRevGFP DNA
ratio on the x-axis in duplicates. The level of GFP fluorescence was analyzed
by FACS and the percent of relative fluorescence of Rev-GFP fusion protein
expression was determined for each mix.,
)
fin Fig. 1A. To initially test efficacy of these siRNAs, we
constructed a Rev-GFP expression cassette that contains the
coding sequence of rev with its expression serving as a
Fig. 3. Inhibition of Env-GFP fusion protein expression by the R2 siRNA. Cells
were transfected with two different ratios of pU6R2/pEnvGFP as indicated and
analyzed for inhibition of expression of the Env-GFP protein by the R2 siRNA.
The results shown are an average of duplicate experiments.
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plasmid ratio, for each construct, was co-transfected into 293T
cells and the level of GFP expression was monitored daily for
level of fluorescence by observing under a UV-microscope.
Cells were harvested 2 days post-transfection for FACS
analysis. Controls included samples from cells only mock-
transfected and pSP72 co-transfected with pRevGFP. The level
of fluorescence was quantified relative to cells transfected with
pRevGFP and pSP72 (Fig. 1B). The results are an average of
three independent experiments. In cells treated with the R2
siRNA, fluorescence was reduced by 89%. An increase in
fluorescence was observed in cells transfected with pU6R1 or
pU6R3 relative to pSP72 indicating that the R1 and R3 siRNAs
had no activity on their cognate substrate RNA molecules. We
observed no cytotoxicity side effects due to siRNA introduc-
tion as determined by comparing cells transfected with
plasmids containing or lacking siRNA (data not shown).
Interestingly, GFP expression increased by 2.5-fold in cells
transfected with pU6R1 plasmid compared to cells transfected
with pSP72. This result implies that the R1 siRNA had activity
that enhances rev-GFP expression by a mechanism that is not
currently clear. The GFP expression in cells transfected with
pU6R3 is also slightly elevated. R2 siRNA activity was further
examined on the substrate in samples transfected with different
concentrations of pU6R2 plasmid while maintaining the same
concentration of substrate. The results showed a reduction in
fluorescence with increasing amount of DNA, indicating the
effect of siRNA on the substrate Rev-GFP correlated with the
amount of effector input DNA (Fig. 1C). However, with a 50
times increase in DNA concentration, there was a 2–3-fold
change in inhibition of target molecules, indicating that the
decrease in target molecule did not correlate in a linear fashion
with increased amounts of DNA. The lack of linear correlation
may be due to the differences in promoter strength between
CMV and U6.
To examine that the low level GFP expression observed in
siRNA treated cells was due to activity on target RNA
molecules, the levels of Rev-GFP transcripts were examined
by Northern blot analysis (Fig. 2). RNA samples isolated from
cells co-transfected with a plasmid containing each siRNAFig. 2. Northern blot analysis of rev-GFP transcripts in the presence of siRNAs.
Each lane, except Lane M, represents RNA samples from pRevGFP-transfected
293T cells. M is a negative control wherein RNA was obtained from mock
treated cells. U6 represents samples from cells receiving the PolIIIU6 promoter
without siRNA. R1, R2 and R3 designate samples from cells transfected with
siRNA expression plasmids pU6R1, pU6R2 and pU6R3, respectively. The
RNA blot was hybridized to [a-32P]dCTP-labeled DNA fragment representing
GFP. The level of Rev-GFP transcripts normalized to that of the h-actin and
relative Rev-GFP expression was determined.expression cassette and pRev-GFP were hybridized to a GFP
probe. RNA blots were also hybridized with actin probe to
monitor and normalize for RNA recovery. The Rev-GFP
transcripts were not targeted by R1 or R3 siRNAs confirming
the results of GFP expression at the protein level. Similar to the
expression at the protein level, the mRNA level was also
elevated in cells that received the R1 or R3 siRNA. In cells
transfected with R2 siRNA, however, the Rev-GFP expression
was significantly reduced thus validating the results of the
protein expression. The R2 siRNA, therefore, is an effective
siRNA which acts on its substrate RNA molecule.
Inhibition of SIV Env expression by the R2 siRNA
The target for siRNA R2 is in exon 2 of SIV rev (nucleotide
position 9185–9203) which also contains part of the env
sequence. To determine whether the R2 siRNA can also silence
Env expression, the env sequence was placed in frame with
GFP to create a fusion Env-GFP protein (pEnvGFP). The level
of Env-GFP expression was examined in cells co-transfected
with the R2 siRNA expression cassette (pU6R2) or a control
plasmid which lacks the siRNA (pSP72). When a ratio of DNA
tranfection of Env-GFP:R2 siRNA of 1:66 was used, fluores-
cence was reduced by 87% compared to cells receiving the
control pSP72 which lacked the siRNA expression cassette
(Fig. 3). The effect of the R2 siRNA was more pronounced
when increased amount of the pU6R2 was used. When a ratio
of Env-GFP:R2 siRNA of 1:200 was co-transfected, the level
of fluorescence was reduced by 95%. The R2 siRNA,
therefore, affects the expression of both Rev and Env proteins.
Inhibition of SIV replication in cells transduced with SFV-1
vector carrying siRNAs
Recombinant SFV-1 vectors containing siRNAs were
constructed in order to determine the efficacy of siRNAs
delivered via foamy virus vector on SIV replication (Fig. 4).
Since the R2 siRNA effectively inhibited the expression of
both Rev-GFP and Env-GFP proteins, we placed the R2 siRNA
Fig. 4. Schematic representation of SFV-1 vector containing siRNA expression cassette. The siRNA expression cassette was inserted upstream of the internal CMV
promoter in the SFV-1 vector. Each siRNA was expressed under the control of PolIII U6 snRNA promoter. The sense and antisense strands of the siRNA were
separated by four nucleotides and five T nucleotides were attached at the 3V end as a termination sequence.
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The pSFV-1U6R2/zeo was transfected along with packaging
plasmids into 293T cells generating vector particles used to
infect CEMx174 cells which are susceptible to SIV infection.
As a control, cells receiving no SFV-1 vector were used
(mock). The transduced cells were challenged with SIV at an
moi of 0.001. Supernatants from the infected cells were
harvested every 2 days for 17 days to determine the levels of
virus production by monitoring for reverse transcriptase (RT)
enzyme activity and the capsid p27 protein by ELISA. As
shown in Fig. 5, in the mock transduced cells, SIV replication
was detected 3 days post-infection increasing exponentially
thereafter until cell lysis began. In cells transduced with the R2
siRNA, the value of RT activity and p27 protein began to drop
at day 9 compared to mock transduced cells with inhibition of
virus replication reaching 68%. The reduction in RT and p27
remained until day 17 indicating that the SFV-1 vector
delivered R2 siRNA had effectively inhibited SIV replication.Fig. 5. Inhibition of SIV replication by SFV-1 vector-mediated siRNA expression. CE
anti-rev/env (R2) siRNA. These transduced cells were challenged with SIVmac239
from cell cultures challenged with SIV. The reverse transcriptase activity is shown in
in triplicates and assayed for reverse transcriptase. (B) The SIVencoded p27 was det
the indicated time intervals.The reason for the delay of the inhibitory effect of R2 until day
9 may have to do with the time taken to accumulate enough
siRNA that had an impact on a replicating virus. The R2
siRNA, therefore, is an efficient inhibitor of SIV replication
and can substantially reduce virus replication.
We further examined the efficacy of the SFV-1 siRNA
transduction to suppress virus replication in cells in which an
SIV infection had been established. CEMx174 cells were
infected with SIV239 at an moi of 0.005, and at 24 h post-
infection, the cells were then transduced with SFV-1 vector
containing the R2 siRNA at an moi of 50. As controls, infected
cells receiving no SFV-1 vector (mock) or SFV-1 vector that
express GFP without siRNA were used. Supernatants from the
cells were harvested every 3 days beginning day 6 post-
infection until day 15 and virus production was monitored by
RT enzyme activity. As shown in Fig. 6, SIV replication in
control cells was detected at day 6 increasing exponentially
until cell lysis began. In cells treated with the R2 siRNA,Mx174 cells were transduced with SFV-1 vector (pSFV-1U6R2/zeo) expressing
at an moi of 0.001. (A) Reverse transcriptase analysis of supernatants harvested
counts per minute (cpm). Samples were harvested at the indicated time intervals
ermined by ELISA from the same cultures where supernatants were harvested at
Fig. 6. Inhibition of virus replication by siRNA in cells where SIV infection is
established prior to siRNA delivery. CEMx174 cells were infected with SIV at
an moi 0.005, then at 24 h post-infection, were transduced with the SFV-1
vector (pSFV-1U6R2/zeo) expressing anti-rev/env (R2) siRNA at an moi of 50
or mock. Samples were harvested at the indicated time intervals in triplicate and
assayed for reverse transcriptase. The reverse transcriptase activity is shown in
counts per minute (cpm).
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reduction in replication reaching 73% or 80% when compared
to controls of SIV harvested from mock transduced or SFV-1
vector expressing GFP, respectively. SFV-1-mediated siRNA
transduction was therefore also effective in cells where SIV
infection was established.
Discussions
We have established the basis for the utility of SFV-1
vectors in gene therapy applications. The observation that no
disease is associated with foamy viruses argues that foamy
virus vectors can be safe for human gene therapy. Foamy virus
vectors can efficiently transduce a variety of cells including
clinically important cell types. In this study, we have shown
that vectors developed from simian foamy virus containing
siRNAs can effectively inhibit SIV replication. Using direct
transfection methods, the R2 siRNA that targets the SIV rev
and env genes efficiently reduced the expression of Rev-GFP
and Env-GFP fusion proteins. The replication of SIV was
significantly inhibited in cells transduced with SFV-1 vector
carrying the R2 siRNA.
Direct transfection of sense and antisense siRNA expression
cassettes that target HIV showed inhibition of target-GFP
fusion protein expression by 70–90% (Lee et al., 2002; Park et
al., 2003). The hairpin type siRNA is equally effective to that
of the duplex made from independent complementary ssRNAs.
Our hairpin type R2 siRNA was also effective and showed an
89% to 95% fluorescence reduction in the SIV rev-GFP and
env-GFP fusion expressions. The R2 activity was, therefore,
comparable to that which was observed for the HIV studies.
Lentivirus vector-mediated delivery of siRNAs that target HIV
showed up to a 1–3 log reduction in virus replication (Lee et
al., 2003; Li et al., 2003). Similar results were also obtained
with siRNAs delivered via an AAV vector (Han et al., 2004).
The lower efficacy observed with foamy virus vector deliveredsiRNA may have to do with less efficient gene delivery into
CEMx174 cells. Recent experiments revealed that the bet gene
product is important in blocking the antiviral activities of
cellular APOBEC3 protein (Lochelt et al., 2005; Russell et al.,
2005). The lack of the bet gene product from the foamy vector
system may reduce gene delivery into CEMx174 cells, while in
293T cells where APOBEC3 is absent, vector production and
transduction are efficient. Transduction of primate CD34+
hematopoietic progenitor cells by a retroviral vector expressing
an RRE/TAR decoy or antisense/ribozyme inhibits HIV
replication in myelomonocytic and differentiated T cells
produced in long-term culture (Bahner et al., 1996; Bonyhadi
et al., 1997; Rosenzweig et al., 1997; Su et al., 1997). These
findings demonstrate the ability of antiviral strategies to inhibit
HIV replication in primary myelomonocytic and T cells after
transduction of CD34+ progenitor cells and expansion.
Furthermore, after reconstitution of human bone marrow cells
implanted in SCID mice (SCID-hu bone) with the transduced
hematopoietic stem cells, a significant number of donor derived
CD14+ bone marrow cells were found to express the anti-HIV
molecules (Bonyhadi et al., 1997; Su et al., 1997). When
donor-derived thymocytes from reconstituted SCID-hu are
infected with HIV, in vitro, significant inhibition of virus
replication was observed (Bonyhadi et al., 1997; Su et al.,
1997). Similarly, progeny of CD34+ hematopoietic progenitor
cells transduced with siRNAs show resistance to HIV
challenges (Banerjea et al., 2003).
While these studies achieved variable levels of antiviral
gene activities, a major limitation with most anti-HIV gene
therapy studies is the lack of an effective safe vector that will
efficiently deliver antiviral genes into the host. Although
lentivirus vectors are refined and promising, vectors based on a
pathogenic virus for human gene therapy will always remain a
public concern. In general, the discovery of leukemia in 2 of 11
children receiving gene therapy using a retroviral vector has
caused serious concern about the adverse effect of retroviral
vectors in gene therapy applications (Hacein-Bey-Abina et al.,
2003; Marshall, 2002, 2003). Comparative studies to evaluate
integration sites between MuLVand HIV in hematopoietic cells
revealed reduced level of risk for genotoxic events with
lentivirus vectors (De Palma et al., 2005). Contrary to this
observation, another study demonstrated the development of
liver tumor in mice treated intravenously with a lentivirus
vector (Themis et al., 2005). Since foamy virus genomes
integrate into the host genome, the potential to disrupt or
activate a gene exists. However, studies of foamy virus genome
integration analysis into the host chromosomes are required to
demonstrate if there are integration preferences that reflect the
non-pathogenic phenotype of foamy virus infection. Our results
showed suppression of SIV replication with the delivery of
siRNAs into target cells by non-pathogenic foamy virus
vectors. In addition to being non-pathogenic, foamy virus
vectors can efficiently transduce human hematopoietic cells
and comparative studies have indicated that foamy virus
vectors are superior in transducing CD34+ cells (Leurs et al.,
2003). Therefore, SFV-1-mediated siRNA delivery into human
hematopoietic stem cells for HIV therapy will have safe and
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can be established through the SIV system. The rush to perform
antiviral gene therapy experiments in humans without devel-
oping effective safe vectors and protocols could hamper
progress. Novel vector systems, such as SFV-1, for the SIV
gene therapy model can establish a basis for effective anti-HIV
gene therapy.
Materials and methods
Cell cultures
The 293T (human embryonic kidney fibroblasts) and
CEMx174 (human T cell line) cell lines were obtained from
American Type Culture Collection (Rockville, Md.). Cells
were grown in Dulbecco’s modified Eagle medium or in RPMI
medium for 293T cells or CEMx174 cells, respectively,
supplemented with antibiotics and 10% fetal calf serum.
Construction of plasmids
The plasmid pRevGFP was constructed by inserting the SIV
rev cDNA (nucleotide positions 6784–6853 spliced in to
9062–9309) upstream of a coding sequence of GFP in frame.
Similarly, to generate an SIV env-GFP fusion protein, the
coding region of SIV env (nucleotide sequence position 6706–
9374) was cloned upstream to the GFP coding region creating
the plasmid pEnvGFP. The fusion proteins were expressed
under the control of the human cytomegalovirus (CMV)
immediate early gene promoter. Hairpin siRNAs that target
different regions in rev (R1, R2, R3) were chemically
synthesized with a four nucleotide gap between sense and
antisense having the restriction enzyme sites SalI and XbaI
attached at the 5V and 3V ends for cloning, respectively. The
target sequences for each of the siRNAs are shown in Table 1.
The pTZU6+27 plasmid (Paul et al., 2002) which contained the
PolIII U6 snRNA promoter for siRNA expression was
provided by David R. Engelke of the University of Michigan
(Ann Arbor, MI). To create expression cassettes for each
siRNA, the PolIII U6 snRNA promoter was removed from
pTZU6+27 with restriction enzyme digests of BamHI and XhoI
and cloned into pSP73 creating the plasmid pU6. Each siRNA
was cloned into SalI–XbaI sites of pU6 while attaching five T
termination nucleotides at the 3V end of the hairpin structure as
described previously (Paul et al., 2002), thus generating
expression cassettes of pU6R1, pU6R2 and pU6R3.
A simian foamy virus type 1 (SFV-1) vector, pSFV-1AMgp/
zeo containing a GFP expression cassette, was used to deliver
and express the siRNAs in the target cells (Fig. 4). pSFV-
1AMgp/zeo was derived from pCCGL. The construction of
pCCGL was described previously (Park et al., 2002). The
translation initiation ATG codons were destroyed in both gag
and pol genes in pCCGL to create pCCGLDgp. In pSFV-
1U6R2, the R2 siRNA expression cassette was cloned into
pSFV-1AMgp upstream the internal CMV promoter. The pSFV-
1U6R2 was modified by replacing the CMV-GFP expression
cassette with a CMV promoter controlling the expression of thezeocine and GFP genes (pSFV-1U6R2/zeo). A ribosomal entry
sequence (IRES) was placed between zeocine and GFP to
allow efficient expression of GFP. All constructs were
confirmed by sequencing double-stranded DNA templates
using the Perkin-Elmer Applied Biosystem Division (PE/
ABD) 373A automated sequencer.
DNA transfections
Transfections of 293T cells were carried out in six well
plates by the liposome-mediated method with the reagent
LipofectAMINE according to the manufacturer’s recommenda-
tions (Life Technologies, Inc., Gaithersburg, Md.). Cells were
seeded at a density of 4.5105 in 6-well plates and co-
transfected with 2 Ag of an effector plasmid for siRNA
expression and varying concentrations (0.01–0.5 Ag) of
substrate plasmid containing the expression cassette for the
target-GFP fusion protein. The medium was replaced with
fresh DMEM containing 10% FBS 24 h after transfection.
Cells were harvested 2 days post-transfection to determine the
effect of siRNA on the substrate RNA molecule. Cells were
prepared for flow cytometry analysis to determine the level of
GFP expression.
RNA blot hybridization
Total RNA was extracted from 293T cells co-transfected
with siRNA and target expression plasmids using QIAGEN’s
RNeasy kit (QIAGEN Inc., Valencia, CA). The RNA was
treated with 10 units of RNAse-free DNAse (Ambion, Austin,
TX) for 30 min at 37 -C. Ten micrograms of total RNA was
fractionated on a 1.2% agarose gel containing 2.2 M
formaldehyde and transferred to a nylon membrane (Magna-
Graph; Micron Separations Inc., Minnetonka, MN) for
hybridization. The membrane was hybridized under a stringent
condition to [a-32P]dCTP-labeled DNA fragment representing
GFP or PCR amplified h-actin fragment as a control. To isolate
small size RNA molecules, 293T cells were harvested 2 days
after transfection of siRNA expression plasmids and RNA was
isolated using the MirVana RNA isolation kit (Ambion, Inc.,
Austin, TX). Ten micrograms of RNAwas denatured with 1 M
glyoxal and 50% DMSO in 10 mM sodium phosphate buffer,
pH 7.0, at 50 -C for an hour. RNAs were eluted on a 3%
Nusieve (3:1) agarose gel in sodium phosphate buffer (pH 7.0).
The RNA was transferred to Hybond N+ membrane
(Amersham Bioscience UK Limited, England) overnight by
capillary transfer and hybridized to the [g-32P]ATP-labeled 19
nucleotide R2-specific antisense probe. For the detection of
internal control RNA, U6 RNA-specific antisense oligonucle-
otide, 5V-TGCTAATCTTCTCTGTATCGT-3V was used as a
probe after labeling the 5V end with [g-32P]ATP.
Production of packaged SFV-1 vectors and transduction
SFV-1 vector particles were produced by co-transfecting
293T cells with SFV-1 vector containing anti-SIV sequences
(Fig. 4) and the packaging plasmid CRU5GPEpolA. The
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et al., 2002). To enhance foamy virus vector production, cells
were stimulated 6–8 h post-transfection with 10 mM sodium
butyrate (Sigma-Aldrich, St. Louis, MO) for 12 h and super-
natants were harvested 4 days post-transfection. Viral super-
natants were clarified by centrifugation at 5000 rpm for 20 min
then by passaging through a 0.45 Am filter. The vector particles
were further concentrated 100-fold by using the Apollo
Centrifugal Spin Concentrators, 70 kDa (Orbital Biosciences,
Topsfield, MA). The amounts of SFV-1 vector produced were
titered on fresh 293T cells plated at a density of 2.5104 per
well in 24 well plates. Seventy-two hours after infection, cells
were monitored and scored for GFP fluorescent under a
microscope with UV light source. Transduction of CEMx174
cells was performed by spin-inoculation as previously de-
scribed (Mergia et al., 2001). Briefly, cells were seeded at a
density of 5105 per well, centrifuged at room temperature for
10 min at 2500 rpm and resuspended in 300 Al [multiplicity of
infection (moi) of 4] of SFV-1 vector particles. The resus-
pended cells were then spun at 1500 rpm for 1 h as described
previously (Bahner et al., 1996; Bunnell et al., 1995) and the
infection procedure was repeated 8 h later. Four days post-
infection, the culture medium was replaced with RPMI
supplemented with 400 Ag/ml of zeocine to enrich for
transduced cells.
SIV virus preparation and challenges
The SIVmac239 provirus DNA was transfected into
CEMx174 cells using the DEAE-Dextran method as previously
described to produce viral particles (Naidu et al., 1988). Virus
replication was monitored by cytopathic effect and reverse
transcriptase assay. RT activities of the culture supernatant from
SIV challenge experiments were analyzed as described
previously (Willey et al., 1988). Briefly, 10 Al of supernatant
was taken after centrifuging virus infected cell culture for 10
min at 10,000 rpm to remove cell debris. The supernatant was
mixed in 50 Al of 50 mM Tris–HCl (pH 8), NP-40 (0.1%),
dithiothreitol (1 mM), KCl (40 mM), EGTA (0.5 mM), MgCl2
(1 mM) and BSA (100 Ag/ml). RT activity was assayed in
triplicate with 3H-dTTP as a precursor and poly rA/oligo dT as
a template/primer. TCID50 values were determined by serially
diluting supernatants of each virus stock, infecting CEMx174
cells and counting syncytia formed cells.
The CEMx174 cells transduced with SFV-1 vector contain-
ing anti-SIV sequences were challenged with SIV at a
multiplicity of infection of 0.001 using the DEAE-dextran
method as reported previously with minor modifications
(Vzorov and Compans, 2000). Briefly, cells were treated with
20 Ag/ml DEAE-dextran for 2 h and washed with RPMI
medium before SIV infection. Two hours after infection, the
medium was replaced with fresh RPMI medium supplemented
with 10% FBS. The SIV infected cells in triplicate wells of a 6-
well plate were incubated at 37 -C under 5% CO2 atmosphere
and culture supernatants were collected every 2 days. The
efficacy of SFV-1 siRNA vector was also examined in
CEMx174 cells in which an SIV infection was establishedwith SIV239 at an moi of 0.005. Infected cells were transduced
with moi 50 of SFV-1 vector containing anti-SIV siRNA 24
h after SIV infection. The level of SIV production from SFV-1
vector transduced cells was monitored by RT enzymatic
activity and the amount of capsid p27 was analyzed by the
SIVantigen capture assay kit (Coulter Corporation, Miami, FL)
according to the manufacturer’s directions.
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